Tumor Mutational Burden and Response Rate to PD-1 Inhibition
Explore this paper's citation graph
Summary
In a survey of the spectrum of mutational burdens in 27 types of cancers, there was a correlation between an increased mutational burden and the response to checkpoint inhibition of PD-1 and PD-L1.
- Type
- letter
- Published
- 2017-12-20
- Cited by
- 2,734
- References
- 5
- Access
- Open access
- OpenAlex
- https://openalex.org/W2779221466
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:40997969
Keywords
Medicine, Cancer research, Oncology, Internal medicine
References
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- PD-1 blockade in tumors with mismatch repair deficiency.
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
- Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade
Cited by
- Systemic treatment of advanced non-small cell lung cancer: controversies and perspectives
- Liquid biopsies for hepatocellular carcinoma
- Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA
- Immunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistance
- Tumor mutational burden standardization initiatives: Recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions
- 18F-FDG PET/CT in non-small-cell lung cancer patients: a potential predictive biomarker of response to immunotherapy.
- Conducting a Virtual Clinical Trial in HER2-Negative Breast Cancer Using a Quantitative Systems Pharmacology Model With an Epigenetic Modulator and Immune Checkpoint Inhibitors
- Recurrent Metastatic Penile Cancer Patient with Positive PD-L1 Expression Obtained Significant Benefit from Immunotherapy: A Case Report and Literature Review
- Antibiotics in cancer patients: is the verdict still out?
- Impact of age on genetics and treatment efficacy in follicular lymphoma
- Toxicities associated with immunotherapies for hematologic malignancies.
- Consolidation systemic treatment after radiochemotherapy for unresectable stage III non-small cell lung cancer.
- Re: Jose Luis Perez-Gracia, Yohann Loriot, Jonathan E. Rosenberg, et al. Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens. Eur Urol 2018;73:462-8.
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- Functional genomics: paving the way for more successful cancer immunotherapy
- Clinical implication of tumor mutational burden in patients with HER2-positive refractory metastatic breast cancer
- Microsatellite instability in prostate cancer by PCR or next-generation sequencing
- Re: Michael B. Atkins, Elizabeth R. Plimack, Igor Puzanov, et al. Axitinib in Combination with Pembrolizumab in Patients with Advanced Renal Cell Cancer: A Non-randomised, Open-label, Dose-finding, and Dose-expansion Phase 1b Trial. Lancet Oncol 2018;19:405-15.
- Immuno-Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD-L1 Testing May Not Be Enough.
- Immunotherapy of Esophageal Cancer: Current Status, Many Trials and Innovative Strategies
Related papers
- DETERMINING QUALITY REQUIREMENTS AT THE UNIVERSITIES TO IMPROVE THE QUALITY OF EDUCATION
- Genentech taps Affimed’s antibodies
- Enxerto livre de arteria epigastrica inferior: avaliacao hemodinamica e angiografica pre e pos-operatoria
- Cardiac retransplantation in children.
- Avaliacao hemodinamica sequencial em transplante de coracao
- Thoracoscopic discectomy and fusion in the treatment of spinal deformities
- Outcomes and Complications in Patients with Uncontrolled Diabetes Undergoing Cervical Spine Surgery
- Pediyatrik Konjenital Kalp Cerrahisinde Anestezi Uygulamalarımız